Möchten Sie immer auf dem neuesten Stand bleiben?

Oslo, Norway, July 17, 2017: Photocure ASA (OSE: PHO), announced today that the United States Centers for Medicare & Medicaid Services (CMS) has released the Proposed Rule outlining its 2018...

Oslo, Norway, 23 May 2017: Photocure ASA (OSE: PHO) today reported a Hexvix/Cysview revenue growth of 9% to NOK 36.5 million in the first quarter of 2017 (Q1 2016: NOK 33.5), with an EBITDA of NOK...

Photocure will present its first quarter report on Tuesday 23 May 2017 at Hotel Continental, Oslo, Norway. Additionally, Dr. Daneshmand will present the new phase 3 study results with Blue Light...

21.5% of patients with recurrence of bladder cancer would have been missed if BLFC with Cysview had not been used in the surveillance setting, which is highly significant (p<0.0001)    ...

Oslo, Norway, May 12th, 2017: Photocure ASA (Photocure, PHO:OSE), today announced that a Phase 3 trial investigating Blue Light Flexible Cystoscopy (BLFC(TM)) with Cysview®/Hexvix® in the...

Oslo, Norway, May 5 2017: Photocure ASA (OSE:PHO), today announced the appointment of Jeremy Bahr as Chief Business Officer. "I am pleased to welcome Jeremy to the Photocure team, strengthening our...

Dr. Jan Hendrik Egberts - Board ChairmanDr. Johanna HolldackMs. Gwen Melincoff Oslo, Norway April, 28, 2017: Photocure ASA (OSE:PHO), a specialty pharmaceutical company and world leader in...

Oslo, 27 April 2017: Photocure ASA (OSE: PHO), held its annual general meeting on 27 April 2017 at 17:00 hours (CET). All proposals were resolved as presented in the notice convening the general...

Data on US Registry Study for BLC(TM) with Cysview/Hexvix will also be Presented at AUA Oslo, Norway, April 26, 2017: Photocure ASA (Photocure, PHO:OSE), today announced that results from the BLFC...

 Oslo, 24 April 2017: Photocure ASA (OSE: PHO). Bente-Lill Bjerkelund Romøren has as chairperson of the board of directors of PHO received proxies to vote for 1,389,360 shares at the annual general...